Pharma procurement teams spend a lot of time on price—rebates, contracting, tender strategy, and budget impact. But there’s a quieter, higher-stakes variable hiding in plain sight: Paragraph IV filings.
If you’re buying branded drugs (or managing suppl…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re a pharma executive, investor, or in-house counsel, you already know the headline number: patent terms are “20 years from filing.” But in Asia-…

Drug patent expiry dates aren’t just legal milestones—they’re commercial calendars. And most companies still treat them like static facts instead of dynamic growth levers.
Here’s the agitation: if you’re waiting until a patent is “about to expire” to b…

Sell the Line Before the Patent Breaks: A Business Development Guide for Solid-Dose Equipment Suppliers Targeting Pre-LOE Generic Expansion
The most expensive moment to win a customer is after the patent clock runs out.
In generic pharmaceuticals, “tim…

The “Smarter Monopoly” Debate Is Here—and It’s About More Than Patents
Drug pricing isn’t just a policy argument anymore—it’s a design problem. And the design question at the center of today’s debate is deceptively simple: what should happen when a dru…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
The market doesn’t wait for you to catch up.
If you’re a sterile manufacturing supplier serving biologics, the “cliff” is real: Loss of Ex…

The patent clock doesn’t just tick—it gets reset.
For years, the public conversation around drug pricing has focused on one villain: “bad patents.” But the more uncomfortable truth is that the system is often designed to outlast generic competition—n…

Patients aren’t asking “about patents.” They’re asking, “Will I be able to afford my medicine?”
If you’ve spent any time around healthcare, you know the real question behind the search bar isn’t legal—it’s personal.
A growing share of patients are turn…